title: Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.
abstract: Determining the factors that lead to successful enrollment of patients in cancer control clinical trials is essential as cancer patients are often burdened with side effects such as pain, nausea, and fatigue. One promising intervention for increasing enrollment in cancer control trials is the National Cancer Institute's Community Clinical Oncology Program (CCOP). In this article, we examined CCOP staffing, policies, and procedures associated with enrollment in control trials. Data were obtained from three sources: the online CCOP, MB-CCOP, and Research Base Management System, CCOP Annual Progress Reports, and a survey of CCOP Administrators conducted in 2011. We analyzed cancer control trial accrual in 2011 among 46 CCOPs using multivariate regression. Three factors were significant predictors of accrual. First, having a team of staff dedicated to enrolling patients in control and prevention trials, compared to having no dedicated staff, was associated on average with an additional 30 patients enrolled in control trials (p<0.05). Second, CCOPs that recognized physicians for enrolling a large number of patients compared to CCOPs that did not recognize high enrolling physicians enrolled on average an additional 25 patients in control trials (p<0.05). Lastly, the number of cancer control trials available was also associated with enrollment (β=5.50, p<0.00). Our results indicate that CCOPs looking to increase enrollment in control trials should consider dedicating a team of staff to enroll patients in these types of trials. In addition, CCOPs or other volunteer research systems looking to increase physician participation should consider recognizing high enrolling physicians.
authors.affiliation: Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, NC 27599-7411, USA. jacobssr@live.unc.edu
authors.forename: Sara R
authors.initials: SR
authors.lastname: Jacobs
authors.forename: Bryan J
authors.initials: BJ
authors.lastname: Weiner
authors.forename: Lori M
authors.initials: LM
authors.lastname: Minasian
authors.forename: Marjorie J
authors.initials: MJ
authors.lastname: Good
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods*; D019058:Community Networks / Q000458:organization & administration*; D003430:Cross-Sectional Studies; D006801:Humans; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000517:prevention & control / Q000628:therapy*; D018579:Patient Selection; D015397:Program Evaluation; D012108:Research Personnel / Q000458:organization & administration*; D014481:United States